pd-0325901 has been researched along with Facies* in 2 studies
2 other study(ies) available for pd-0325901 and Facies
Article | Year |
---|---|
New BRAF knockin mice provide a pathogenetic mechanism of developmental defects and a therapeutic approach in cardio-facio-cutaneous syndrome.
Cardio-facio-cutaneous (CFC) syndrome is one of the 'RASopathies', a group of phenotypically overlapping syndromes caused by germline mutations that encode components of the RAS-MAPK pathway. Germline mutations in BRAF cause CFC syndrome, which is characterized by heart defects, distinctive facial features and ectodermal abnormalities. To define the pathogenesis and to develop a potential therapeutic approach in CFC syndrome, we here generated new knockin mice (here Braf(Q241R/+)) expressing the Braf Q241R mutation, which corresponds to the most frequent mutation in CFC syndrome, Q257R. Braf(Q241R/+) mice manifested embryonic/neonatal lethality, showing liver necrosis, edema and craniofacial abnormalities. Histological analysis revealed multiple heart defects, including cardiomegaly, enlarged cardiac valves, ventricular noncompaction and ventricular septal defects. Braf(Q241R/+) embryos also showed massively distended jugular lymphatic sacs and subcutaneous lymphatic vessels, demonstrating lymphatic defects in RASopathy knockin mice for the first time. Prenatal treatment with a MEK inhibitor, PD0325901, rescued the embryonic lethality with amelioration of craniofacial abnormalities and edema in Braf(Q241R/+) embryos. Unexpectedly, one surviving pup was obtained after treatment with a histone 3 demethylase inhibitor, GSK-J4, or NCDM-32b. Combination treatment with PD0325901 and GSK-J4 further increased the rescue from embryonic lethality, ameliorating enlarged cardiac valves. These results suggest that our new Braf knockin mice recapitulate major features of RASopathies and that epigenetic modulation as well as the inhibition of the ERK pathway will be a potential therapeutic strategy for the treatment of CFC syndrome. Topics: Animals; Benzamides; Benzazepines; Diphenylamine; Disease Models, Animal; Drug Synergism; Ectodermal Dysplasia; Embryo, Mammalian; Facies; Failure to Thrive; Female; Gene Expression Regulation; Gene Knock-In Techniques; Genes, Lethal; Heart Defects, Congenital; Histone Deacetylase Inhibitors; Histone Demethylases; Humans; Liver; Male; MAP Kinase Kinase Kinases; Mice; Mice, Transgenic; Mutation; Myocardium; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyrimidines; Signal Transduction; Skull | 2014 |
Continual low-level MEK inhibition ameliorates cardio-facio-cutaneous phenotypes in zebrafish.
Cardio-facio-cutaneous (CFC) syndrome is caused by germline mutations in KRAS, BRAF and MEK1/2. The highly selective and potent MEK inhibitors that have been developed as anti-cancer agents hold potential as therapeutics for CFC syndrome. We have previously shown that the effects of CFC mutations on zebrafish gastrulation can be prevented by a 1-hour treatment with MEK inhibitors within a specific developmental time-window. However, MEK activity is essential for normal development and PD0325901 treatment outside this treatment window leads to additional developmental defects in MEK-dependent tissues. We now test ten different doses of PD0325901 at six developmental time points and assess the effects on body axis length, heart development and craniofacial structures in zebrafish embryos. Notably, we find that a continuous low-level dose of PD0325901 that has only minor inhibition of MEK activity can prevent the action of both the common CFC BRAF(Q257R) kinase-active allele and the BRAF(G596V) kinase-impaired mutant allele through the first 5 days of development. These results provide a detailed study of the effects of PD0325901 in development and show that, unlike in cancer, which requires robust inhibition of MAPK signalling, a partial reduction in phospho-ERK1/2 activity is sufficient to moderate the developmental effects of BRAF(CFC) mutations. Topics: Animals; Benzamides; Diphenylamine; Ectodermal Dysplasia; Embryo, Nonmammalian; Facies; Failure to Thrive; Heart Defects, Congenital; Mitogen-Activated Protein Kinase Kinases; Phenotype; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Small Molecule Libraries; Zebrafish | 2012 |